Glaxo failed to warn of diabetes drug risk

The widow and son of a Texas man who was taking a GlaxoSmithKline Plc diabetes drug at the time of his fatal heart attack claims the drugmaker failed to warn about the drug’s risks, according to a lawsuit.

The claim involves rosiglitazone, which is sold under the brand names Avandia and Advandamet. Investors have been bracing for a flood of litigation against Glaxo after a widely publicized medical report suggested Avandia increases the risk of heart attack.

The lawsuit was filed Tuesday by relatives of Larry Alan Stanford in the U.S. District Court for the Eastern District of Texas.

“Glaxo knew or should have known that its rosiglitazone drug greatly increased plaintiffs’ risks of having a heart attack and/or other negative cardiovascular consequences or of causing sudden cardiac death,” the lawsuit said.

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

Implantable ‘artificial pancreas’ could help diabetes patients control their blood sugar   Joslin researchers find drugs are effective for diabetic macular edema in new trial   New superfoods could help key protein keep bodies healthy   Mobile app on emergency cardiac care aids best decisions in seconds   Train your heart to protect your mind   Poor quality of life may affect teens’ diabetes management   Mass. General study identifies path to safer drugs for heart disease, cancer   FDA denies approval to wider use of J&J’s blood clot preventer   FDA Warns of Potential Risk of Severe Liver Injury With Use of Dronedarone   Tweaking MRI to track creatine may spot heart problems earlier, Penn Medicine study suggests   Cancer drug protects against diabetes   Amino acid’s increase is suspected in diabetes